[18F]FDOPA PET and clinical features in parkinsonism due to manganism

Document Type

Article

Abstract

Manganese exposure reportedly causes a clinically and pathophysiologically distinct syndrome from idiopathic Parkinson's disease (PD). We describe the clinical features and results of positron emission tomography with 6-[18F]fluorodopa ([18F]FDOPA PET) of a patient with parkinsonism occurring in the setting of elevated blood manganese. The patient developed parkinsonism associated with elevated serum manganese from hepatic dysfunction. [18F]FDOPA PET demonstrated relatively symmetric and severely reduced [18F]FDOPA levels in the posterior putamen compared to controls. The globus pallidum interna had increased signal on T1-weighted magnetic resonance imaging (MRI) images. We conclude that elevated manganese exposure may be associated with reduced striatal [18F]FDOPA uptake, and MRI may reveal selective abnormality within the internal segment of the pallidum. This case suggests that the clinical and pathophysiological features of manganese-associated parkinsonism may overlap with that of PD.

Medical Subject Headings

Adult; Antiparkinson Agents (therapeutic use); Brain (metabolism); Carbidopa (therapeutic use); Drug Combinations; Female; Fluorodeoxyglucose F18; Gait; Humans; Levodopa (therapeutic use); Magnetic Resonance Imaging; Manganese Poisoning (blood, complications); Middle Aged; Parkinson Disease (drug therapy, etiology, pathology); Positron-Emission Tomography; Radiopharmaceuticals

Publication Date

4-1-2005

Publication Title

Movement disorders : official journal of the Movement Disorder Society

ISSN

0885-3185

Volume

20

Issue

4

First Page

492

Last Page

496

PubMed ID

15648057

Digital Object Identifier (DOI)

10.1002/mds.20381

Link to Full Text

Share

COinS